EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function
Status:
Unknown status
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The long-term use of calcineurin inhibitors in the maintenance phase after kidney
transplantation is associated with typical adverse effects, such as potential contribution to
progressive impairment of renal function, hypertension, and metabolic abnormalities.
This 15 month study with a safety follow up is undertaken to evaluate the potential benefit
of an alternative treatment strategy to the chronic use of CNI. It will establish, through a
comparative design, the superior protection of kidney function provided by chronic usage of
basiliximab over tacrolimus early post-transplantation using EDC kidneys.
Phase:
Phase 3
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre